WFNMB Post Congress Symposium Prostate Cancer: PET and Theranostics Cairns Convention Centre, Queensland, Australia April 26-27, 2018 THURSDAY 26th APRIL.

Slides:

Advertisements

Similar presentations

ARDENT MEETING Andrej Sipaj October 14 th, ABOUT ME Born and raised in Slovakia Studied: BEng in Mechanical Enginnering at UOIT, Canada MASc in.

Advertisements

Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD

PET/CT in Oncology George Segall, M.D. Stanford University.

Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.

NCI Workshop on Phase ‘0’ Trials: Rationale and Goals  Reduce the FDA’s Exploratory IND to practice: New process for investigators interested in early.

British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.

D.G.Lewis Department of Medical Physics Velindre Cancer Centre Whitchurch, Cardiff RT-GRID: Grid Computing for Radiotherapy.

In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.

Radiotherapy for Brain Tumours What do I need to know? Dr Matthew Foote Radiation Oncologist Princess Alexandra Hospital Queensland.

JHSGR 16 th April 2011 Dr Lee Man Kit Derek.  The value of PET in staging adenocarcinoma (e.g. colorectal cancer) is well established Tomoharu T. et.

COC ADVOCACY TRACK Overview of National Oncology Issues & Key COA Initiatives for 2015 Ted Okon Orlando, Florida April 23, 2015.

PET/CT & PET/MRI Radiopharmacy

HIGH-INTENSITY FOCUSED ULTRASOUND By: Sahil Bilung and John Lee.

AMERICAN COLLEGE OF RADIOLOGY March 23, OUR MISSION To foster the ongoing development of widely acceptable consistent imaging.

CTOS: A Herman Suit Legacy Michael A. Simon, MD The University of Chicago.

Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:

The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,

M. Wissmeyer Department of Nuclear Medicine, University of Berne (Inselspital) PET/CT in Radiation Oncology: Current Evidence and Future Perspectives.

Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for.

One and a half year experiences in Germany Ekkasit Tharavichitkul Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University,

1 NOPR 2006: Results and Lessons Learned 2010 Annual AHRQ Conference NOPR 2006: Results and Lessons Learned 2010 Annual AHRQ Conference Bruce E. Hillner,

Kara Penney Bone Cancer. Osteosarcoma Chondrosarcoma The Ewing Sarcoma Family of Tumors (ESTFs) Types of Bone Cancer.

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

WALIS Marine Group Workshop Perth Convention Centre 12 March 2008.

Hodgkin’s Lymphoma Hodgkin’s Lymphoma Disease in which malignant (cancer) cells form in the lymph system Type of cancer that develops in.

Retirement Systems, Issues and Solutions Australia, post Cooper and the International Environment.

Introduction to Tumor Board

PET/MR in Oncology: Non– 18 F- FDG Tracers for Routine Applications R2 丁建鑫.

Welcome to Asian Institute of Medical Sciences

Atoms for Health Prof. Dr. Werner Burkart Skolkovo Conference on: Accelerators and Radiation Technologies for the Future of Russia Saint Petersburg,

Molecular Imaging “101” The Role of Molecular Imaging in Cancer Briefing and Roundtable Washington, DC July 22, 2008 Martin G. Pomper, MD, PhD Russell.

Nuclear imaging for prostate cancer: What’s new?

Omega Best Cancer Hospital - India

Volume 64, Issue 5, Pages (November 2013)

An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer Marco Bandini, Giorgio Gandaglia, Nicola Fossati, Francesco.

Using PET/CT in Prostate Cancer

This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in.

Using PET/CT in Prostate Cancer

Klinikum rechts der Isar, Technische Universität München

Prostate cancer: Radioisotope diagnostic/ therapeutic methods

CINP Thematic Meeting on Treatment Resistant Depression

ICWES 15 Review & ICWES 16 Preview

UAB medical Center, Birmingham VA Medical Center

Updates in Prostate Cancer Prepared for GP master class – Sept 2016

Can the American Thyroid Association Risk of Recurrence Predict Radioiodine Refractory Disease in Differentiated Thyroid Cancer Eur Thyroid J 2016;5:

Nat. Rev. Urol. doi: /nrurol

Overview of Nuclear Technologies in Healthcare

New Tracers for Prostate Cancer Imaging

Medical Imaging Technologies

FIRST NATIONAL FLIM WORKSHOP

First clinical experience with PSMA617

AN OVERVIEW OF THE BONE METASTASES PROGRAM

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology? Laila König, Henrik.

The Breed Health Symposium

Jaden D. Evans, MD, Krishan R

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic.

Dr T P E Wells 13 July 2018 Breast SSG Bath

We look forward to welcoming you to Sydney in November 2017!

Volume 64, Issue 5, Pages (November 2013)

Updates in Detection and Management of BCRPC

Clinical and Translational Radiation Oncology

Nat. Rev. Urol. doi: /nrurol

PWRI Quarterly Meeting Tentative Agenda

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology? Laila König, Henrik.

A Theranostic “SMART” Aptamer for Targeted Therapy of Prostate Cancer

European Urology Oncology

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Constantinos Zamboglou, Matthias Eiber, Thomas R

Medical Applications of Particle Physics.

Presentation transcript:

WFNMB Post Congress Symposium Prostate Cancer: PET and Theranostics Cairns Convention Centre, Queensland, Australia April 26-27, 2018 THURSDAY 26th APRIL Session 1 Clinical Overview of Prostate Cancer and Functional Imaging Options 8.00-8.05 Welcome and overview A/Prof Paul Roach Sydney, Australia 8.05-8.30 Prostate cancer in 2018: a clinical overview A/Prof Declan Murphy Melbourne, Australia 8.30-8.55 Functional imaging with PET/CT: Choline and 18F-Fluciclovine Prof Hossein Jadvar Los Angeles, USA 8.55-9.20 68Ga PSMA: chemistry Prof Clemens Decristoforo Vienna, Austria 9.20-9.45 Functional Imaging with 68Ga PSMA PET/CT Prof Richard Baum Bad Berka, Germany 9.45-10.10 68Ga PSMA: interactive cases / pearls & pitfalls Dr Geoff Schembri Sydney, Australia 10.10-10.40 Morning tea Session 2 Primary Staging of Prostate Cancer 10.40-11.10 Surgeon’s perspective: Imaging and treating primary prostate cancer 11.10-11.35 Conventional Imaging (CT, bone scan, MRI): role and limitations Dr Francesco Ceci Los Angeles, USA 11.35-12.00 Functional imaging with 68Ga PSMA PET/CT: role and limitations Prof Arturo Chiti Milan Italy 12.00-12.15 Trials and evidence: what we know, don’t know but need to know A/Prof Louise Emmett Sydney, Australia 12.15-12.45 Panel discussion, Q&A and challenging cases A/Prof Declan Murphy & A/Prof Michael Hofman 12.45-13.30 Lunch Session 3 Biochemical Recurrence / Failure (BF) 13.30-13.55 Radiation Oncologist’s perspective: Imaging and treating BF A/Prof George Hruby Sydney, Australia 13.55-14.20 Conventional Imaging of BF (CT, bone scan, MRI): role and limitations 14.20-14.45 Functional imaging of BF with 68Ga PSMA PET/CT: role and limitations Prof Arturo Chiti Milan Italy 14.45-15.00 15.00-15.30 A/Prof Emmett, A/Prof Hruby and Prof Ian Davis 15.30-16.00 Afternoon Tea Session 4 Recent developments: New Tracers and New Technologies 16.00-16.25 New and future tracers for diagnosing prostate cancer 16.25-16.50 PET/MRI: is it better than PET/CT? 16.50-17.00 Panel discussion, Q&A, close FRIDAY 27th APRIL Session 5 Systemic Therapy of Prostate Cancer Treating prostate cancer: state of the art radiation oncology Treating prostate cancer: state of the art systemic therapy Prof Ian Davis Melbourne, Australia 8.55-9.15 177Lu PSMA therapy: Overview, logistics, practicalities 9.15-9.40 177Lu PSMA therapy: local experience, indications, evidence base A/Prof Michael Hofman Melbourne, Australia 9.40-10.05 Session 6 Systemic therapy of Prostate Cancer: New and Future Therapeutic Radionuclides 10.05-10.35 177Lu PSMA theranostics: local experience 10.35-11.05 Approach to dosimetry and new α and β therapies for prostate cancer Dr Aviral Singh Bad Berka, Germany 11.05-11.30 223Ra therapy (Xofigo) Prof Homer Macapinlac Houston USA 11.30 Wrap-up and close Proudly sponsored by: